Adaptam Therapeutics, a San Sebastián-based biotech focused on cancer immunotherapies targeting immunosuppressive myeloid cells, closed a €3M (~$3.5M) pre-seed financing round led by Criteria Bio Ventures. Representatives from Criteria Bio Ventures joined Adaptam's board as part of the transaction.
Comments
Want to join the conversation?
Loading comments...